Tasimelteon (Tasimelteon) Patent Expiration, LOE Window & CMS Spending

Tasimelteon (Tasimelteon) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 3 AB generics, $47.8M 2024 CMS Part D & Medicaid spend, and $20,571 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$47.8M
2024 Medicare Part D Spend$31.4M
2024 Medicaid Spend$16.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($20,571 intro WAC)